SCHEMBL3030362

SCHEMBL3030362

C=CCO/N=C(/C)c1ccc(B(O)O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 3/20 0.42
PTBP1 P26599 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 2/20 0.35
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
LPL P06858 3/20 0.34
LIPG Q9Y5X9 3/20 0.34
CA2 P00918 2/20 0.34
CA1 P00915 1/20 0.34
ENPP2 Q13822 1/20 0.34
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13215229 1.00 SMN1; SMN2 (0.51) SMN1; SMN2LMNAPTBP1L3MBTL1MAPK1
SCHEMBL3030363 1.00 SMN1; SMN2 (0.51) SMN1; SMN2LMNAPTBP1L3MBTL1MAPK1
SCHEMBL16202061 0.82 SMN1; SMN2 (0.54) SMN1; SMN2LMNAPTBP1L3MBTL1MAPK1
SCHEMBL13215248 0.81 SMN1; SMN2 (0.53) SMN1; SMN2LMNAPTBP1L3MBTL1MAPK1
SCHEMBL6269349 0.81 SMN1; SMN2 (0.53) SMN1; SMN2LMNAPTBP1L3MBTL1MAPK1
SCHEMBL5197529 0.78 SMN1; SMN2 (0.50) SMN1; SMN2LMNAPTBP1L3MBTL1MAPK1
SCHEMBL5197523 0.78 SMN1; SMN2 (0.50) SMN1; SMN2LMNAPTBP1L3MBTL1MAPK1
SCHEMBL16202013 0.75 SMN1; SMN2 (0.48) SMN1; SMN2LMNAPTBP1L3MBTL1MAPK1
SCHEMBL14578045 0.74 CA2 (0.47) SMN1; SMN2LMNAPTBP1L3MBTL1MAPK1
SCHEMBL12663148 0.74 NPC1 (0.56) SMN1; SMN2LMNAPTBP1L3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1572663-B1 BIPHENYLCARBOXAMIDES BAYER CROPSCIENCE AG (DE) 2013-03-20 EP disclosed
US-20100216849-A1 BIPHENYLCARBOXAMIDES DUNKEL RALF 2010-08-26 US disclosed
US-7728019-B2 Biphenylcarboxamides BAYER CROPSCIENCE AG (DE) 2010-06-01 US disclosed
US-20080085924-A1 Biphenylcaboxamides BAYER CROPSCINCE AG (DE) 2008-04-10 US disclosed
EP-1572663-A1 BIPHENYLCARBOXAMIDES Bayer CropScience AG (DE) 2005-09-14 EP disclosed
WO-2004054982-A1 BIPHENYLCARBOXAMIDES BAYER CROPSCIENCE AG (DE) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085924-A1 Biphenylcaboxamides AHR, Q6ZSR9, DDT SMN1; SMN2 3276/4885LMNA 1108/4885PTBP1 3165/4885
US-20100216849-A1 BIPHENYLCARBOXAMIDES AHR, DDT, MRPL21 SMN1; SMN2 3297/4885LMNA 765/4885PTBP1 3055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.